An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer.
|
| Abstract |
Ninety evaluable metastatic breast cancer patients refractory to hormonal therapy and combinations of cyclophosphamide, methotrexate, 5-fluorouracil, and doxorubicin were treated with a low-dose mitomycin regimen, i.e., 10 mg/m2 intravenously every 28 days. In order to minimize thrombocytopenia, dose de-escalations related to platelet counts were made. One patient (1%) had a complete response and 17% had partial responses for a median duration of 4 months. The time to progression for the responders and stabilized patients was similar; however, the responders and stabilized patients lived significantly longer than did the progressors. Hematologic toxicity was minimized because of planned de-escalations in mitomycin dosage. Perivenous ulceration, both immediate and delayed (8%), congestive heart failure (2%), and heart-renal failure with malignant hypertension (2%) resulted in significant morbidity, including two drug-related deaths. Although mitomycin dosages were successfully titrated according to platelet counts in this group of chemotherapy-refractory patients, prolonged use of this drug in adjuvant or early metastatic breast cancer patients is not recommended because of potentially irreversible thrombocytopenia.
|
|---|---|
| Authors | R H Creech, R B Catalano, M K Shah, H Dayal |
| Journal | Cancer (Cancer) Vol. 51 Issue 6 Pg. 1034-40 (Mar 15 1983) ISSN: 0008-543X [Print] United States |
| PMID | 6821868 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!